Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

Vimseltinib is intended to treat tenosynovial giant cell tumour. Credit: crystal light / Shutterstock. The European Medicines Agency (EMA) has accepted for review the marketing

Fol­low­ing the FDA’s May re­lease of long-await­ed draft guid­ance ex­plain­ing how com­pa­nies can win des­ig­na­tions for cer­tain cell and gene ther­a­py “plat­form” tech­nolo­gies, com­pa­nies like

A new on­col­o­gy drug end­point, based on what’s known as min­i­mal resid­ual dis­ease, gained the back­ing of FDA ad­vi­sors, po­ten­tial­ly open­ing the door to new